Loading the company…
Loading the company…
In 2025, Glaukos reported engagement with 2,595 surgeons and other clinicians in the states MedaRep covers, worth $657K in consulting, speaking, meals and travel for its device products, the most in California ($105K to 469). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: California ($105K, 469 engaged), Florida ($42K, 204 engaged), Texas ($41K, 229 engaged), South Dakota ($31K, 13 engaged), Pennsylvania ($28K, 55 engaged).
In the last ten years FDA made 28 decisions for Glaukos (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2022 (6). The latest was on 2026-10-01.
| Family | Decisions on record |
|---|---|
| Cataract & MIGS | 47 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-10-01 | PMA | P170043-S023 | Glaukos® iStent inject® W Trabecular Micro-Bypass System, Glaukos® iStent inject® W Trabecular Micro-Bypass System with · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2026-04-08 | PMA | P080030-S027 | iStent® Trabecular Micro-Bypass Stent System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2025-02-24 | PMA | P170043-S019 | iStent inject® W Trabecular Micro-Bypass System Model iS2 · Change Design/Components/Specifications/Material |
| 2025-01-13 | PMA |
| P170043-S020 |
| iStent inject Trabecular MicroBypass System · Labeling Change - PAS |
| 2024-03-28 | PMA | P080030-S026 | iStent® Trabecular Mjcro-Bypass Stent System, Model GTS100 · Labeling Change - PAS |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Glaukos.